HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Complete-type DiGeorge syndrome treated by bone marrow transplantation.

Abstract
BMT was carried out on a patient with DiGeorge syndrome who suffered recurrent infections after birth. At 13 months of age, 8.0 x 10(8)/kg of bone marrow nuclear cells were infused from an HLA-identical sibling using only anti-thymocyte globulin to prevent rejection. Donor DNA was not detected on microsatellite polymorphism by PCR. At 19 months of age, a second BMT from the same donor was carried out using busulfan and cyclophosphamide as conditioning. DNA examination of bone marrow showed chimerism at day 18 and complete donor origin at day 28. Seven months post-BMT, the numbers of CD3-, CD4- and CD8-positive cells were in the normal range. BMT is thus an effective therapy for DiGeorge syndrome.
AuthorsT Matsumoto, N Amamoto, T Kondoh, M Nakayama, T Takayanagi, Y Tsuji
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 22 Issue 9 Pg. 927-30 (Nov 1998) ISSN: 0268-3369 [Print] England
PMID9827824 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antigens, CD
Topics
  • Antigens, CD (immunology)
  • Bone Marrow Transplantation
  • DiGeorge Syndrome (immunology, therapy)
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • T-Lymphocytes (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: